Optimizing Precision Oncology workflows will reduce costs and make very effective treatments available to more patients, sooner!
Idealized Precision Oncology workflows:
1: Start with Liquid Biopsy early detection.
2: Proceed with precision treatments optimized for each individual's cancer's specific characteristics.
3: Succeed with treatment validating research reporting and Minimal Residual Disease surveillance.
Legacy medical methodology has been researching and treating cancer as a medical condition. With the onset of precision cancer antigen targeting, and other drug interventions the successful treatment of cancer is becoming more of a bio-engineering, data engineering and care coordination opportunity.
More efficient Lab- to-clinic processes save lives and reduce costs. Wider geographic reach increases the number of Patients treated and research data gathered.
The FDA is evolving to adapt to the special requirements of Precision Oncology with streamlined Genomic drug utilization. procedures.
Earlier detection. Faster, more precise cancer characterization
Driving broader access to appropriate, effective translational care. Accelerating research validation and mainstreaming of better medicines.
Local Primary Care Provider orchestration of best-available precision Oncology treatment with specialist team and pharma coordination. Easy HIPAA compliant data sharing using Sanguia's secure convenient remote care team collaboration system.
Robotic gripper adaptations, and wet lab management system integrations. scaled up sequencing. Nuclear medicine pharmacy and production expertise. Sample and treatment logistics.
Phylo phylo.bio launches with $13.5 million seed round from Andreeson. Their product: Biomni Lab, accelerates AI-native biology, allowing scientists — working across physical and computational fields — to plan, author, execute, and collaborate on complex research tasks with state-of-the-art agentic AI in a fully integrated workspace.
Drawn by high demand and Medicare reimbursement rules that reward expensive drugs and procedures, private equity firms have acquired hundreds of oncology practices nationwide, reshaping how cancer care is delivered and financed. This transformation is not merely structural—it has fundamentally altered the incentives that guide treatment decisions. https://bullmooseproject.org/posts/private-equity-in-cancer-care